perindopril powder (Santa Cruz Biotechnology)
Structured Review

Perindopril Powder, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/perindopril powder/product/Santa Cruz Biotechnology
Average 93 stars, based on 2 article reviews
Images
1) Product Images from "Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats"
Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats
Journal: Pharmaceuticals
doi: 10.3390/ph18030358
Figure Legend Snippet: Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.
Techniques Used: Control
Figure Legend Snippet: Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.
Techniques Used:
Figure Legend Snippet: Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.
Techniques Used:
Figure Legend Snippet: Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.
Techniques Used:
Figure Legend Snippet: Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.
Techniques Used:
Figure Legend Snippet: Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.
Techniques Used: Injection
Figure Legend Snippet: Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.
Techniques Used:
Figure Legend Snippet: Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.
Techniques Used:
Figure Legend Snippet: Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.
Techniques Used:
Figure Legend Snippet: Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.
Techniques Used:
Figure Legend Snippet: Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).
Techniques Used: Staining, Control
Figure Legend Snippet: Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.
Techniques Used: Immunohistochemical staining, Staining, Control, Immunostaining, Injection, Expressing
Figure Legend Snippet: Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).
Techniques Used: Control, Disruption
Figure Legend Snippet: Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).
Techniques Used: Construct